Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Retail investors didn’t even get the opportunity to vote re

<< Previous

Bullboard Posts

Next >>

Comment by Jayjayton Jul 23, 2020 6:30pm

93 Views

Post# 31311042

RE:RE:RE:RE:Retail investors didn’t even get the opportunity to vote re

jack400 how many years did kaly is in th industrie? Most of big investors did no see and value to invest here. Why because the compagny had bad rputation. 90% stock down . No value to shareholders since the begining.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property